Background: The Auryon 355-nm laser atherectomy system (AngioDynamics, Inc) showed a low rate of target-lesion revascularization (TLR) at 6-month follow-up in the EX-PAD-03 investigational device exemption study and the Auryon single-center experience (SCE) in treating infrainguinal arteries. In this study, we present the 1-year outcomes of the Auryon SCE study on TLR in all comers at a single center.
Methods: The Auryon SCE was a retrospective study that evaluated the outcomes of all comers treated with the Auryon laser for infrainguinal arterial disease. There was no TLR seen at 6-month follow-up. We present the TLR rate at 1 year in the same cohort of patients. TLR rates were obtained from medical record review of patients enrolled in the study who had completed office visit follow-up at 1 year. Secondary endpoints included unplanned major amputation and total mortality. Kaplan-Meier survival analysis was performed to estimate the freedom from TLR rate following index procedure. Statistical differences were analyzed for ankle-brachial index (ABI) between baseline and 1 year.
Results: A total of 56 patients (65 procedures, 70 lesions) were enrolled. The mean age was 70.9 ± 10 years, with 66.1% males, 48.2% diabetics, and 25% demonstrating limb ischemia. Of the 70 lesions, 31.4% had severe calcification, 38.6% were chronic total occlusions, and 48.6% were de novo disease (in-stent restenosis, 29.6%). Stenting was performed in 24/70 lesions (34.3%), with 11/70 (15.7%) bailout procedures. Embolic filters were used in 26/65 procedures (40%). The majority of treated lesions were femoropopliteal (90.0%); of all procedures, 29.2% had 2 or more prior interventions. Drug-coated balloon usage was 47.1% Lutonix (BD/Bard), 27.1% In.Pact (Boston Scientific), and 1.4% both in all lesions treated. Distal embolization occurred in 1/65 procedures (1.5%). At 1 year, mortality occurred in 3/56 patients (5.4%). Of 65 limbs treated, 2 (3.1%) had major amputation at 1 year. The probability of freedom from TLR was 83.7%.
Conclusion: In a realworld cohort of patient with complex disease, the Auryon laser had excellent freedom from TLR at 1 year.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.25270/jic/22.00155 | DOI Listing |
J Vasc Interv Radiol
December 2024
Department of Interventional Radiology, Mallinckrodt Institute of Radiology, 510 S Kingshighway Blvd, St. Louis, MO 63110.
Purpose: To evaluate the primary use of a laser atherectomy-thrombectomy system in patients with acute limb ischemia (ALI).
Materials And Methods: A single-center retrospective review of patients presenting with ALI (14 days or less) from August 2021 to February 2024 treated primarily with a laser atherectomy-thrombectomy system (Auryon; Angiodynamics, Queensbury, New York) was performed. Technical success was defined by resolution of the acute occlusion with adequate inflow and outflow with pedal signals detectable by handheld doppler ultrasound.
Am J Cardiol
May 2024
AngioDynamics, Latham, New York.
The 355 nm Auryon laser (AngioDynamics, Inc., Latham, New York) has been shown to be effective and safe in treating various morphology lesions in the femoropopliteal arteries. There are limited data on the Auryon laser in treating below-the-knee (BTK) arteries in patients with chronic limb-threatening ischemia.
View Article and Find Full Text PDFCardiovasc Revasc Med
December 2023
CVPath Institute, Gaithersburg, MD, USA; University of Maryland, School of Medicine, Baltimore, MD, USA. Electronic address:
Cardiovasc Revasc Med
December 2023
Endovascular Consultants of Colorado, Lone Tree, CO 80124, United States of America. Electronic address:
Background: While endovascular approaches are considered first line treatment for stenosis or occlusion of the lower limb arteries, major dissections and embolic events remain procedural risks. Newer technologies are needed which limit these complications while achieving desired clinical outcomes.
Methods: The Auryon atherectomy system (AngioDynamics) consists of a 355-nm wavelength solid-state Nd:YAG short pulse laser combined with dedicated optical catheters.
J Invasive Cardiol
July 2022
Midwest Cardiovascular Research Foundation, 630 East 4th Street, Davenport, IA 52803 USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!